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We have developed a new single cycle lentiviral vector, SIVsmH4i-SC27.1, as a potential SIV/HIV-1 vaccine candidate. This viral vector is
capable of expressing all of the SIV gene products but is limited to one round of infection. The vector was created by mutating 27 codons dispersed
among the viral vif, env, and nef genes to block protein function, attenuate viral replication/infectivity, and reduce the ability of the virus to manipulate
the host immune system. To complement the env and nef replication defects, SC27.1 was pseudotyped with the VSVG glycoprotein to allow particle
entry. The vifmutation was complemented by producing particles from an APOBEC3G-negative cell line, and the Vif protein defect was validated by
showing that the single cycle virus lost most of its infectivity when particles were produced in presence of APOBEC3G. To deal with the problem of
an antibody response to the VSV G protein in a vaccination strategy, two additional serotypes of the VSV G protein were used to create pseudotyped
virus particles, andwe observed no cross-neutralization activity for two of the pseudotyped particles with a potent neutralizing antiserum to one of the
VSVG proteins. We detected moderate inhibition of infectivity in normal human andmacaque sera, especially to the New Jersey serotype of VSVG,
but as a heat sensitive activity, presumably complement mediated. These particles can be used in a prime-boost strategy to determine if a single cycle
lentiviral vaccine vector capable of expressing all of the viral gene products holds promise in inducing immunity and protection to an SIVsm
challenge.
© 2007 Elsevier Inc. All rights reserved.Keywords: Lentiviral vector; SIV; HIV-1 vaccine; VSV GIntroduction
Second generation HIV-1 vaccine candidates are in or near
human testing. These include DNA vaccines, protein boosts, and
single cycle virus vectors for a variety of poxviruses, alphaviruses,
adenovirus, adeno-associated virus, and more (see http://www.
iavireport.org/trialsdb/). A logical extension of this concept is a
single cycle retrovirus that can serve as its own vector for the
delivery of the viral gene products. This approach is distinguished
from an attenuated virus that goes through multiple rounds of
replication but with the attendant potential for evolution to⁎ Corresponding author. CB7295 Lineberger Building Rm 22-006, UNC
Center For AIDS Research, University of North Carolina at Chapel Hill, Chapel
Hill, NC 27599, USA. Fax: +1 919 966 8212.
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doi:10.1016/j.virol.2007.09.023increased pathogenesis. Several designs of single cycle vectors are
in development with some initial promising results (Baliga et al.,
2006; Evans et al., 2004, 2005; Kuate et al., 2003).
There are potential concerns regarding integrating vectors that
were realized with the induction of cancer through insertional
activation in a gene therapy trial that employed amurine leukemia
virus (MLV) vector (Hacein-Bey-Abina et al., 2003). While this
particular example is difficult to generalize due to the possible
contribution of the gene insert in the retroviral vector (discussed
in McCormack and Rabbitts, 2004), these cases do serve to
reinforce the idea that the potential effects of the vector need to be
considered.
Lentiviruses are intrinsically different in their biology compared
to oncogenic retroviruses, including MLV, where the potential for
insertional activation of cellular oncogenes is well known. There is
no evidence that any lentivirus causes tumors in spite of chronic
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reason for the difference in the disease types among different
lineages of retroviruses is not known, one possible difference that
could provide amechanistic explanation is the use in lentiviruses of
trans acting transcriptional factors, like Tat for HIV-1. The Tat
protein targets the TAR sequence on short viral transcripts,
localizing P-TEFb (which contains CDK9/Cyclin T1) to the viral
transcription unit to promote processive RNA synthesis through
phosphorylation of the C-terminal domain of RNA polymerase II
(reviewed in Rice and Herrmann, 2003). This mechanism is
distinct from the transcriptional enhancement of oncogenic
retroviruses, which attract transcription factors to the LTR that
can remodel chromatin regionally (Nusse et al., 1984; Short et al.,
1987). It is also distinct from HTLV-1, which uses its tran-
scriptional transactivator protein Tax as an adaptor protein to
promote assembly of a transcription factor complex but without
the localization effect of the Tat-TAR interaction (Kwok et al.,
1996; Giebler et al., 1997; Lu et al., 2002). Thus, the HIV-1
transactivation protein appears to limit its transcriptional impact on
the host genome to the provirus, with greatly reduced potential to
impact cellular genes including oncogenes.
In this study, we developed a defective genome derived from
the SIVsmH4i infectious and pathogenic molecular clone
(Hirsch et al., 1989a,b). The single cycle vector carries 71
mutations in 27 different codons dispersed among three viral
genes. This mutated molecular clone can generate infectious
virus particles capable of a single round of infection when
transfected into producer cells and pseudotyped with the VSV G
protein. The attractive features of this approach are the ability to
express all of viral proteins for presentation to the immune
system, and the targeting of cells other than the normal target
cell of HIV/SIV, i.e. CD4+ T cells.
Results
Design and construction of the single cycle vector SC27.1
Wemutated 27 codons, dispersed among three viral genes, in
the infectious SIVsm molecular clone of SIVsmH4i (Hirsch
et al., 1989b). We first generated subgenomic clones of
SIVsmH4i to allow simplified protocols for introducing the
mutations then regenerated the full-length clone. The mutations
were selected such that the final viral genome would be able to
express all of the viral gene products, and would be able to
create a virus particle that, when pseudotyped, could initiate
only one round of replication. The viral genes env, vif, and nef
were chosen for mutagenesis with three or more mutations in
each gene that were designed to allow protein expression as an
immunogen but block protein function (Table 1).
We took advantage of the large amount of information
known about the function of the viral Env protein to make
numerous targeted mutations to ablate multiple functions. We
first mutated three Arg residues to Ala upstream of the gp120/
gp41 cleavage site to disrupt gp120/gp41 processing (Bosch
and Pawlita, 1990). We next mutated three Phe residues to Ser
in the fusion peptide domain just downstream of the gp120/
gp41 cleavage site to inhibit its activity in membrane fusion. Inaddition, two Trp residues were mutated to Ala in the C-terminal
heptad repeat of gp41, to disrupt the coiled-coil intermediate
of Env-mediated membrane fusion (Salzwedel et al., 1999).
Finally, two stop codons were introduced at the upstream
boundary of the gp41 cytoplasmic tail domain to create a
truncated form of the Env protein, to improve Env surface
expression (Spies and Compans, 1994; Edwards et al., 2002). In
total, 10 codons were mutated in env directed at four distinct
determinants of Env protein function (Table 1).
The viral protein Vif mediates the degradation of the cellular
proteins APOBEC3G/F to prevent their encapsidation in the virus
particle, which would otherwise lead to deamination of newly
synthesized viral DNA in a subsequent round of infection
(Sheehy et al., 2002; Harris et al., 2003;Mangeat et al., 2003).We
mutated the highly conserved motif YFPC to AAPA (Table 1).
The YF/AA mutations and the C/A mutation have each been
reported to the lower infectivity of HIV-1 to between 1% and 15%
(Simon et al., 1999).
The viral Nef protein is a multifunctional protein whose
functions include down modulation of the immune response
through MHC class I internalization, down modulation of the
viral receptor CD4, increases in viral infectivity, and interaction
with PakII (Wei et al., 2003). Five conserved sequence motifs in
the nef gene were targeted for mutagenesis. First, three of
the positions encoding amino acids that function in myristyla-
tion (MGXXXSK to MAXXXAA) were mutated to inhibit the
myristylation reaction, Nef membrane targeting, CD4 down-
regulation, and virion infectivity (Harris and Coates, 1993;
Geyer et al., 1999, 2001). Second, three conserved codons
encoding acidic amino acids were mutated to encode Arg, a
mutation that affects retention of MHC class I in the golgi
(Mangasarian et al., 1999). Third, two Pro codons in the SH3-
binding PXXP motif were deleted to disrupt the interaction
between Nef and signaling pathways (Xu et al., 1999; Fackler
et al., 1999; Saksela et al., 1995). Fourth, two Arg codons were
mutated, with these residues having been reported to be
involved in Pak activation (Renkema et al., 1999; Fackler
et al., 2000). Finally, two other pairs of conserved residues
(HXB number 123, 124 DW to AA, and 144, 147 KXXP to
AXXV) were mutated based on the assumption that sequence
conservation implies participation in an important function. In
total, 14 codons encoding conserved residues in Nef were mu-
tated (Table 1). The mutations were incorporated into subclones
of the viral genome which were then reassembled using
convenient restriction enzyme sites (Fig. 1). In total, 27 codons
dispersed in env , nef, and vif genes were changed which in-
cluded 39 nucleotide transversion mutations, 26 nucleotide
transition mutations, and 6 nucleotide deletions.
Part of the attenuation strategy is to make a subsequent round
of replication susceptible to the G to A hypermutation effects of
APOBEC3G/F (Harris and Liddament, 2004). To the extent the
chosen engineered mutations were A to G transitions these would
be susceptible to reversion via the APOBEC3G/F pathway.
However, only 12 of the mutations introduced are A to G
transitions. Given that only a fraction of these mutations could be
reverted through this highly mutagenic pathway, and given the
fact that the mutations are dispersed along 4900 nucleotides of the
Table1
Mutations in SC27.1
Gene Motif s to be changed AA substitution Nucleotide change Function disrupted Reference
env (503)RRxxxxxxxRxKR (503)AAxxxxxxAxGA (8105)AGAAGG→GCTGCT Mutations in gp120/gp41 cleavage
site to disrupt gp120/gp41 processing
Bosch and Pawlita (1990)
(8132)AGA→GCT
(8138)AAGAGA→GCTGCT
(514)FxxxFxxF (514)SxxxSxxS (8150)TTT→TCA Mutations fusion peptide to disrupt
membrane fusion activity
Cao et al. (1993)
(8162)TCT→TCA
(8171)TTT→TCA
(628)WxxW (628)AxxA (8477)TGG→GCG Mutations in gp41 C-terminal heptad
repeat to disrupt coiled-coil
structure and membrane fusion
Salzwedel et al. (1999)
(8486)TGG→GCG
(710)QG (710)Double
stop condon
(8723)CAGGGT→TAGTGA gp41 cytoplasmic tail truncation to
improve Env surface expression
Spies and Compans, (1994),
Edwards et al. (2002)
vif (112)YFxC (112)AAxA (5664)TATTTC→GCTGCA Vif conserved amimo acids mutation
to decrease viral infectivity
Simon et al. (1999)
(5673)TGC→GCT
nef (1)xGxxxSK (1)xAxxxAA (9045)GGT→GCT Mutations in myristylation domain
mutations to disrupt myristylation
reaction and membrane targeting
Geyer et al. (2001), Harris
and Coates (1993)(9057)TCCAAG→GCAGCT
(74)DxDxxD (74)RxRxxR (9306)GAT→CGT Conserved acidic amio acids
mutations which reported to maybe
mediate retention of MHC
class I in the golgi in HIV-1
Geyer et al. (2001)
(9312)GAT→CGT
(9321)AGA→CGT
(89)PxxP (89)σxxσ (9351)CCA deletion Mutations in PXXP motif to disrupt
interaction between Nef and signaling
pathways
Xu et al., (1999), Saksela
et al. (1995)(9360)CCC deletion
(132)RR (132)AA (9450)AGAAGA→GCTGCT To disrupt Nef mediated Pak activation Renkema et al. (1999)
(140)DW (140)AA (9504)GATTGG→GCAGCT Mutations to disrupt SIV medicated
MHC class I down-regulation
Swigut et al. (2000)
(160)KxxP (160)AxxV (9567)AAA→GCT Conserved codons
(9576)CCA→GTG
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way to a functional state of replication appears remote.
Production and titration of single-cycle immunodeficiency viruses
The goal of the design of SC27.1 was to ablate particle
infectivity at the entry step with the mutations in the Env
protein, reduce particle infectivity and the ability to modulate
the immune response with the mutations in the Nef protein, and
make the replication cycle susceptible to the mutagenic effects
of APOBEC3G/F with the mutations in the Vif protein.
However, to make infectious particles it was necessary to com-
plement several of these defects, at least during particleFig. 1. Box cartoon of the genome showing restriction sites and engineered muta
approximate positions of the mutated functional domains dispersed among the vif, eproduction. This was done in two ways. First, the Vif defect
was overcome by producing virus in cells that do not express
APOBEC3G, and we chose 293T cells (Sheehy et al., 2002) for
producing virus particles after transfection of the full-length
(mutated) viral DNA. Second, we complemented both the Env
defect and the Nef virion infectivity defect by pseudotyping the
virus particle with the VSV G protein by including a VSV G
expression vector in the transfection (Reiser et al., 1996; Naldini
et al., 1996; Aiken, 1997; Luo et al., 1998; Chazal et al., 2001).
In this way, we were able to produce infectious virus particles
using the unmutated Gag, Pro, and Pol proteins to make
particles that packaged a viral genome that did not encode
functional Env, Vif, or Nef proteins.tions. Unique restriction sites used to create the construct are indicated. The
nv and nef genes are labeled as ⁎.
Fig. 2. Quantification of viral capsid p27 protein by silver staining after
denaturing gel electrophoresis. Viral particles were prepared from the super-
natant of transfected cells and purified through a sucrose cushion. Highly
purified and quantified SIVmac239/SUPT1-CCR5 CL.30 (a gift of Dr. Jeff
Lifson, NCI, lot P3876) was used as standard virus. (A) Single cycle virus,
(B) SIVsmH4i. Lane 1 to lane 6, virus standard: 230 ng, 115 ng, 57.5 ng,
28.8 ng, 14.4 ng and 7.2 ng capsid protein in each lane, respectively. Lane 7 to
lane 11, virus sample volume: 0.6 μl, 1.2 μl, 2.5 μl, 5 μl and 10 μl of sample in
each lane, respectively.
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vector were cotransfected into 293T cells and the virus particles
were collected in the supernatant medium. An aliquot of the
medium was subjected to centrifugation to concentrate the virus
particles. We used two independent methods to determine the
mass of virus produced by the transfection. First we used an
ELISA to measure the amount of viral p27 capsid (CA) protein
present in the medium after transfection and then after further
purification. The ELISA p27 titer was between 3 and 11 μg/ml
in the supernatant medium and between 31 and 310 μg/ml after
a 36-fold concentration (Table 2). Similar levels of p27 were
produced after transfecting either the parental SIV DNA clone
or the SC27.1 plasmid without the pseudotype expression vec-
tor. These results were further confirmed by examining viral
protein mass by silver staining after polyacrylamide gel elec-
trophoresis under denaturing and reducing conditions. As a
control, we used a highly purified and quantified virus prep-
aration (SIVmac239/SUPT1-CCR5 CL.30) to generate a visual
standard curve. The p27 titer was estimated to be between 20
and 100 μg/ml for the concentrated particles derived by
transfection of the mutant (Fig. 2) and parental plasmid clones
(data not shown). Similar results were obtained when infectivity
was monitored from production through purification (Table 3).
These results document the production and infectivity of the
SC27.1 construct as infectious particles.
Characterization of viral protein expression from
SIVsmH4i-SC27.1 after transfection and infection
The presence of viral proteins encoded in the SC27.1 vector
produced by transfection of 293T cells was characterized by
Western blot analysis and compared to the fully infectious
parental clone. Both the viral Gag and Env proteins could be
detected in the lysate of the transfected cells (Fig. 3). Due to the
cytoplasm tail truncation and cleavage site mutations, the Env in
the SC27.1 lysate was smaller than the full-length gp160 Env
precursor but larger than the processed gp120 SU protein
(Fig. 3A, compare lanes 2 and 3). The Gag proteins were
expressed at levels comparable to the level of expression fromTable 2
p27 titer
Transfected plasmid Supernatant
p27 con. (μg/ml) Volume (ml) Total p27 (μ
Experiment 1
SC27.1/pCIVSV G(Ch) a 3.6 198 712.8
SC27.1/pCIVSG G(I) a 3.5 198 693.0
SC27.1/pCIVSG G(NJ) a 4.5 198 883.1
SIVsmH4i a 3.8 15 57.0
SC27.1 a 4.0 198 672.0
Experiment 2
SC27.1/pCIVSV G(Ch) b 4.1 198 823.7
SC27.1/pCIVSG G(I) b 11.4 198 2257.2
SC27.1/pCIVSG G(NJ) a 4.2 198 833.6
a Transfected plasmids molar ratio molar ratio SC27.1: pCIVSV G=1:2, 10.5 μg
b Transfected plasmids molar ratio SC27.1: pCIVSV G=1:5, 10.5 μg SC27.1 andthe parental clone (Fig. 3B), although when analyzed with a
polyclonal antibody we have consistently observed modestly
reduced processing of Gag when expressed from the SC27.1
vector (Fig. 3C). Supernatant virus was concentrated by
pelleting through a 20% sucrose cushion then analyzed for
particle-associated Gag and Env proteins (Fig. 3D). Gag protein
from cells transfected with the SC27.1 construct could be
detected with or without the inclusion of the VSV G expressionPurified particles Recovery
rate (%)
g) p27 con. (μg/ml) Volume (ml) Total p27 (μg)
31 3.5 108.5 15.2%
/ / / /
48.4 3.5 169.4 19.2%
/ / / /
20.5 6.5 133.3 16.8%
93.02 3.5 325.6 39.5%
310.3 3.5 1086.1 48.1%
43.5 3.5 152.3 18.3%
SC27.1 and 9.5 μg pCIVSV G, total 20 μg DNA.
23.5 μg pCIVSV G total 34 μg DNA.
Table 3
Viral infectivity
Transfected plasmid Supernatant titer Purified particles titer Recovery
rate (%)
(BFU/ml) Total volume (ml) Total BFU (BFU/ml) Total volume (ml) Total BFU
Experiment 1
SC27.1/pCIVSV G(Ch) a 6.34E+4 198 1.26E+7 6.14E+5 3.5 2.15E+6 16.9%
SC27.1/pCIVSG G(I) a 6.64E+4 198 1.31E+7 / / / /
SC27.1/pCIVSG G(NJ) a 2.46E+5 198 4.87E+7 1.01E+7 3.5 3.53E+7 72.6%
SIVsmH4I a 7.2E+5 15 2.15E+6 / / /
SC27.1 a 0 198 0 0 6.5 0 0
Experiment 2
SC27.1/pCIVSV G(Ch) b 2.64E+5 198 5.22E+7 7.55E+6 3.5 2.64E+7 50.6%
SC27.1/pCIVSG G(I) b 4.15E+5 198 8.21E+7 1.87E+7 3.5 6.55E+7 79.7%
SC27.1/pCIVSV G(NJ) a 2.19E+5 198 4.34E+7 4.04E+5 3.5 1.41E+6 86.5%
a Transfected plasmids molar ratio molar ratio SC27.1: pCIVSV G=1:2, 10.5 μg SC27.1, and 9.5 μg pCIVSV G, total 20 μg DNA.
b Transfected plasmids molar ratio SC27.1: pCIVSV G=1:5, 10.5 μg SC27.1, and 23.5 μg pCIVSV G total 34 μg DNA.
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released particles still retained some under-processed Gag
protein relative to the parental virus (Fig. 3D, compare lanes 2
and 3). The Env protein was detected in the parental SIVsm
particles but not in the SC27.1 particles either with or without
the VSV G pseudotype expression vector (Fig. 3D), suggesting
the mutated form of the Env protein failed to package into the
particles. We do not know the cause of the under-processing of
Gag; it is possible this is an effect of an absence of the cyto-
plasmic domain of Env interacting with MA, although we have
not tested this possibility directly.
The above experiment examined the expression of viral
proteins after transfection of the mutagenized genomic clone; we
also wanted to document the expression of the viral proteins after
infection. TZM-BL cells were infected with VSVG-pseudotyped
SC27.1 particles or with the parental SIV. Proteins were
radioactively labeled at steady state (to distinguish input virus
from newly synthesized viral proteins), and the cell lysate and
virus-containing supernatant mediumwere collected at 48 h post-Fig. 3. Western blot analysis of viral protein expression after transfection of producer
B are the analysis of cell lysates from the transfected cells. Viral particles were prepare
a sucrose cushion. Panels C and D are the analysis of viral particles produced from tra
pCIVSV G(Ch); lane 5, SC27.1/pCIVSV G(I); lane 6, SC27.1/pCIVSV G(NJ). The
A), SIVmac251 anti-Gag monoclonal antibody (Panels B and C) or serum pooled finfection. Viral proteins were analyzed using immunoprecipita-
tion and denaturing gel electrophoresis. Cell-associated expres-
sion of Gag p27 was apparent in both pseudotype virus- and
parental virus-infected cells (Fig. 4A). The non-cleaved and
truncated form of Env was detected in the pseudotype SC27.1-
infected cells lysates (Fig. 4B). Particle-associated Gag p27
protein was detected in particles pelleted from the supernatant of
the cells infected with pseudotyped SC27.1 or with the parental
virus (Fig. 4C). These results show that the SC27.1 vector is able
to go through a round of infection then direct subsequent gene
expression.
Validation of the phenotypes of the mutated proteins
To validate whether the vif mutations disrupted Vif protein
function, 293T cells (which do not express APOBEC3G) were
transfected with the SC27.1/VSV G(I) plasmids alone or with
an APOBEC3G expression vector at 4 different molar ratios. As
a control, the parental infectious clone SIVsmH4i was similarlycells. 293T cells were transfected with plasmids as indicated below. Panels A and
d from the supernatant of transfected cells and purified by centrifugation through
nsfected cells. Lane 1, mock; lane 2, SC27.1; lane 3, SIVsmH4i; lane 4, SC27.1/
western blots were probed with SIV anti-Env monoclonal antibody 36D5 (Panel
rom several SIVsm-infected macaques (Panel D).
Fig. 4. Immunoprecipitation of viral proteins after infection of TZM-BL cells with pseudotyped SC27.1. Panels A and B are cell lysates. Panel C is virus pelleted from
the supernatant medium of the TZM-BL cells infected with the indicated virus. Radiolabeled viral proteins were immunoprecipitated by anti-Gag (Panels A and C) or
anti-Env (Panel B) antibodies 48 h post-infection of TZM-BL cells. Lane 1, mock control, 293T cells; lane 2, mock control TZM-BL cells; lane 3, SIVsmH4i
transfected 293 T cells; lane 4, SIVsmh4i infected TZM-BL cells; lane 5, SC27.1/pCIVSV G(NJ) infected TZM-BL cells; lane 6. SC27.1/pCIVSV G(Ch) infected
TZM-BL cells.
Fig. 5. Documentation of the effect of the inactivating vif mutations. 293T cells
were cotransfected with an APOBEC3G expression vector and SC27.1/pCIVSV
G or SIVsmH4i with the plasmid molar ratio as indicated. The infectivity of the
resultant virus was determined by luciferase assay after infection of TZM-BL.
Residual infectivity is recorded as percent of virus in the absence of the
APOBEC3G expression plasmid.
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to infected TZM-BL cells to measure their infectivity (Fig. 5).
The infectivity of the SC27.1 virus was reduced to 25% in the
presence of the APOBEC3G expression vector at a plasmid
molar ratio of 10:1(APOBEC3G: SC27.1), yet the unmutated
parental virus showed essentially no change in infectivity. In-
creasing the APOBEC3G plasmid to a molar ratio to 20:1
dropped the SC27.1 virus infectivity to less than 10% while the
parental virus maintained at least 75% infectivity. These results
confirm a previous study showing that these equivalent vif
mutations significantly lowered the infectivity of HIV-1 (Simon
et al., 1999).
As shown above, the mutations in the env gene resulted in an
unprocessed and truncated Env protein that was defective for
virion incorporation and for particle infectivity. We examined
whether the mutant Env protein could be expressed on the surface
of the cell. As shown in Fig. 6A, there is enhanced surface
expression of the mutated SC27.1 Env protein compared to
the unmutated gp160 protein. An unmutated Env protein with the
C-terminal truncation showed similar enhanced surface expres-
sion, suggesting the other mutations in the SC27.1 Env protein
did not significantly affect its transport to the cell surface. The
enhanced surface expression of the truncated protein was
expected as the cytoplasmic domain contains endocytosis signals
that reduce surface expression of the full-length Env protein
(Rowell et al., 1995; Sauter et al., 1996; Boge et al., 1998; Bowers
et al., 2000;Wyss et al., 2001). Given that themutated Env protein
was expressed on the cell surface but not incorporated into virus
particles, we sought other evidence for the effect of the mutations.
As shown in Fig. 6B, the infection of TZM-BL cells with the
parental virus leads to the formation of syncytia as the infected
cell expresses the Env protein and mediates fusion with nearby
cells expressing the receptor and coreceptor. However, cells
infected with SC27.1 did not induce syncytia with the adjacent
cells. This documents the loss of fusion capacity anticipated with
the mutations that block Env processing, disrupt the hydrophobic
nature of the fusion peptide, and change key residues involved in
the six helix bundle formation.We attempted to document the inability of the mutant Nef
protein to down-regulate surface expression of MHC class I,
however neither the mutant nor the parental Nef proteins could
be shown to down regulate the class I protein (data not shown)
thus precluding a measure of the effect of the mutations. We did
not document protein expression of Vif or Nef due to a lack of
antibody reagents.
Neutralization properties of the pseudotyped SC27.1 particles
An immune response to the vaccine vector is likely to limit
the utility of a boost strategy with a homologous vector. To avoid
the potential impact of the VSV G surface protein inducing
neutralizing antibodies, we made SC27.1 particles pseudotyped
with three different VSVG serotypes: G(I), Indiana; G(NJ), New
Jersey; andG(Ch), Chandipura.We tested the potential for cross-
neutralization between these G proteins by incubating the three
pesudotyped virus preparations and the SIV parental virus in
Fig. 6. Documentation of the effect of the inactivating env mutations. Panel A: Env surface expression. The following env gene constructs were expressed in the VEE
pERK expression vector: SC27.1 gp155, SIVsmH4i gp155, SIVsmH4i gp160. The env gene constructs were cloned into the pERK vector that is an alphavirus replicon
expression vector. For these experiments, a second promoter was included driving GFP expression from the same replicon. Replicon RNAwas generated by in vitro
transcription and introduced into cells by electroporation. Env expression (surface binding of an Env monoclonal antibody) was recorded for the GFP positive cells
since GFP was expressed from the same pERK construct. Panel B: Different Env phenotypes after infection with parental virus SIVsmH4i or SC27.1 either with or
without the VSV G pseudotype. TZM-BL cells were infected with indicated virus and the infected cells were visualized by staining for beta-galactosidase expression.
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antiserum. As shown in Fig. 7A, the VSV G(I) pseudotyped
SC27.1 was neutralized at all dilutions tested (up to 1:6400). In
contrast, there was no neutralization of any of the other viruses
even at the lowest dilution tested (1:100). These results confirm
the serotype classification of the VSV G proteins, even as
pseudotypes, and confirm the potential utility of using different
VSV G-pseudotyped viruses to avoid the problem of an immune
response to the vector in a prime-boost vaccination strategy
(Rose et al., 2000).
VSVG pseudotyped lentiviral vectors have been reported to be
partially inactivated by human complement (DePolo et al., 1999).
To determine the extent to which these VSV G-pseudotyped
single cycle vectors were sensitive to human and macaques sera,
the three different VSV G protein-pseudotyped viruses and the
SIV parent were incubated with 50% normal or heat-inactivated
serum. The residual titer was quantified and the results recorded asFig. 7. Sensitivity of the pseudotyped single cycle vector to neutralization. Panel A: A
at the indicated dilution series prior to infection of TZM-BL cells. Residual infectiv
without the anti-VSV G antiserum. The same viruses were also tested for sensitivity to
pair of points represents one serum sample with each sample tested against the three V
connecting the pairs of points indicates the change in inactivation by the serum befothe percent recovery of infectivity compared to control samples
that were not exposed to human or macaque serum. An overall
sensitivity to inactivation by both human (Fig. 7B) and macaque
(Fig. 7C) serum was observed. The effect was greater with the
macaque serum samples, and VSVG(NJ) wasmore sensitive than
the other two serotypes. Inhibition was largely through a heat-
sensitive component, presumably complement-mediated, and
after heat inactivation of the serum two of the VSVGpseudotypes
(CH and I) had their infectivity enhanced by exposure of the
serum.
The infectivity of SC27.1 is limited to a single cycle of infection
To analyze whether replication competent virus would be
produced by SC27.1-infected cells, we used pseudotyped virus
to infect CEM×174 cells at an MOI of 1 (passage 1), and the
cell supernatant was blind passaged onto fresh CEM×174 cellsnti-VSVG(I) neutralizing serum was incubated with each of the indicated viruses
ity was expressed as percent remaining infectivity compared to virus incubated
nonspecific inactivation by human (Panel B) or macaque (Panel C) serum. Each
SVG pseudotyped viruses and the parental SIVsmH4i virus (wild-type). The line
re (−) and after heat inactivation (+) at 56 °C for 1 h.
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maintained for 2 weeks to assess the appearance of replication
virus using a p27 CA ELISA assay. During passage 1, p27 CA
was detected at a low level from days 2 to 4 post-infection, due
to the input virus and/or the first round of infection. After
the first several days, no p27 CA was detected during the re-
mainder of passage 1 or at any point during passage 2 or passage
3. In contrast, the parental SIV produced a rapid increase in p27
and extensive cells death, even when the infecting inoculum
was at an MOI of 0.01 (data not shown). These results are
consistent with the design of the single cycle virus vector in
being limited to a single round of infection and, at least under
the conditions tested, being unable to revert to replication
competence.
Discussion
Several single cycle vectors have been described previously.
In one case, changes in the gag-pro-pol frameshift site were used
to make the single cycle vector that in the first iteration used the
viral Env glycoprotein for entry (Evans et al., 2004, 2005). This
virus was able to infect macaques and showed transient levels for
circulating virus. Vaccination-challenge studies indicated im-
munization of macaques with this vector stimulates diverse
virus-specific immune responses, and three of four immunized
animals had reduced viral RNA loads of 1–3 log in the
acute phase of infection after challenge. The use of a VSV
G pseudotype with a single cycle vector has been described
previously (Tung et al., 1998). In this approach, the pol and env
genes were truncated then complemented in trans with a
functional pol gene and VSV G. The authors reported no
recombinant virus (although this approach would appear to raise
the problem of recombination during the generation of virus with
the two pol vectors), and they saw reduction in viral RNA load to
below the level of detection in three vaccinated animals after
challenge. No measures of the immune response were reported.
Baliga et al. (2006) inserted a truncated form of cyclin T1 in
place of the env gene and, using a VSV G pseudotype, were able
to generate immune responses in mice. Finally, in another report
of a single cycle vector with an altered tRNA binding site and
four accessory gene deletions, and using a VSV G pseudotype
strategy, a decrease in peak viremia (but not set point) after
challenge with SIVmac239 was seen (Kuate et al., 2003). These
preliminary reports are encouraging and support the investiga-
tion of this class of vaccine vectors. In designing our single cycle
vector, we avoided the full or partial gene deletions that were
used in these previous versions as they remove potential
immunogenic regions. Also, we used only the multiple
mutations in coding regions to limit the vector to a single
cycle rather than the more complex designs of the previous
versions which allows us to limit the components in producing
the vaccine to the vector backbone and the surface protein
expression vector for pseudotyping.
At this point a great deal of information is known about the
structure-function relationship of all of the viral proteins. Thus, it
was possible to create a vaccine vector that was mutated in a
subset of the viral genes (vif, env and nef) with mutationsdesigned to disruptmultiple functions of the protein productwhile
still permitting a single round of infection with the subsequent
expression of all of the viral proteins as potential immunogens.
We were able to accomplish this with a single plasmid repre-
senting the SIV genome and a heterologous viral glycoprotein
expression vector but without the need of a packaging cell line.
The heterologous glycoprotein and the choice of cell lines for
producing virus particles allowed us to complement the mutated
functions missing in the vaccine vector.
There are two important theoretical concerns that must be
addressed when considering a retrovirus single cycle vector.
First, retroviruses integrate into the host genome and, although
not tested directly, the design of this vaccine vector should
permit an integration step during the one round of replication.
The phenomenon of insertional activation as a mechanism of
tumor induction is well known for certain genera of replication
competent retroviruses, including the gammaretroviruses.
However, most of the experience with gammaretrovirus vectors
in gene therapy trials (analogous to a single cycle vector) showed
this risk was minimal. Recently, one trial to introduce the IL2R
gamma(c) gene into children with an immunodeficiency using
an MLV vector resulted in repeated activation of the LMO-2
gene (Hacein-Bey-Abina et al., 2003). It seems likely the gene
insert contributed a second signal in this case, a result not pre-
viously observed in other gene therapy trials.
In contrast, no lentivirus, including HIV-1, has been as-
sociated with tumor induction in its target cell. HIV-1-induced
immunodeficiency is associated with the appearance of tumors
caused by the herpesviruses KSHV and EBV, but there is no
evidence for increased frequencies of CD4+ T cell leukemias or
lymphomas as would be expected if chronic replication put the
target cell at risk for insertional activation of cellular oncogenes
(Frisch et al., 2001; Dal Maso and Franceschi, 2003), in spite of
efforts to implicate HIV infection through such a mechanism
(Mack et al., 2003). It is possible that lentiviruses have a
replication strategy that includes a weak enhancer regulated by
transactivating factors like Tat, and that these factors show a high
degree of specificity for activating transcription from the
provirus, a mechanism that would not favor regional transcrip-
tional activation (Grassmann et al., 2005). In addition, HIV-1
tends to integrate within genes rather than in flanking regions as
do the gammaretroviruses (Schroder et al., 2002; Wu et al.,
2003), which would be more compatible with enhancement of
expression of an undisrupted gene. However, the specificity of
this difference is probably not sufficiently great to account for
the striking biological difference of an absence of tumor
formation associated with lentiviruses. Also, while the mecha-
nism for transactivation expression of the viral genome is well
characterized and requires the cis-acting viral TAR sequence,
transcription of cellular genes has been reported to be altered
by Tat expression (Marzio et al., 1998; Pumfery et al., 2003),
although the mechanism of this effect is not clear. Finally,
infection of T cells by HIV-1 is cytotoxic and this may preclude
the risk of insertional activation; in reality, the potential of
retroviruses to generate deletions during reverse transcription
makes it likely that there are may proviral insertions that encode
defective virus incapable of inducing cytotoxicity.
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for reversion to replication competence and pathogenesis.
Reversion of attenuated viruses to a higher level of replication
capacity has been observed for both HIV-1 and SIV (Koenig
et al., 1995; Ferbas et al., 1996; Goulder et al., 1997; Barouch
et al., 2002). However, these examples typically involve the
reversion of one mutation. Variants with deletion mutations can
still undergo some sequence evolution but replication persists
only at low viral RNA loads, although this can lead to path-
ogenesis (Deacon et al., 1995; Sawai et al., 2000; Alexander et al.,
2003). The potential of APOBEC3G/F to induce hypermutation
further contributes to the genetic instability of the HIV-1/SIV
system (Harris and Liddament, 2004). In designing the SC27.1
vector, we sought to overcome the problem of reversion by
targeting multiple functions in multiple genes for mutagenesis.
Thus, one or even several fortuitous mutations should not permit
reversion to replication competence, which would then provide a
system where selective pressure would come into play. Similarly,
only a minority of the mutations that we incorporated would be
reverted by G-to-A hypermutation, and there is no mechanism
that would focus this deleterious event to the mutated codons. In
the same way, random mutations would not target the mutated
codons and the level of mutagenesis required to revert the
designed mutations would be expected to introduce many other
detrimental mutations at other sites. Our modest attempt to select
for a revertant gave a negative result, although an assessment in an
animal model will be a more rigorous test.
The VSV G pseudotype coat will target the vaccine vector
into cell types that do not normally get infected by HIV/SIV.
Studies of pseudotyped gene therapy vectors in mice have
shown that the VSV G glycoprotein directs infection of non-
dividing cells when given IV, with infection occurring largely
in liver, spleen, and bone marrow cells (Naldini et al., 1996;
Pan et al., 2002). A basic limitation of viral vector systems is
that the animal can develop neutralizing antibodies to the
vector after the first vaccination and these antibodies can pre-
vent subsequent boosting. In the case of VSV G glycoprotein,
anti-G antibodies are highly effective at preventing reinfection
(Rose et al., 2000). Kuate et al. (2003) found the anti-VSV G
antibodies raised in the first inoculation with their single cycle
vector blocked a detectable boost following the second in-
fection. To avoid such a limitation, we have generated three
VSV G protein pseudotyped single cycle viruses that should
allow effective boosting even in the presence of neutralizing
antibodies directed against the previous inoculated vectors.
The VSV G proteins described here, G(I), G(Ch), and G(NJ)
do not elicit cross-neutralizing antibodies to their divergent G
proteins (Rose et al., 2000). Furthermore, additional pseudo-
typing viral attachment proteins could be included in this
strategy to permit continual boosting. Finally, the form of the
SIV Env protein used in this strategy allows surface expression
on the infected cell but is poorly incorporated into the virus
particle, potentially allowing induction of a neutralizing
antibody response to SIV Env that would not target the boost
particles.
The initial HIV-1 vaccine trials have shown no efficacy
but more promising vaccine strategies are well into humantrials (reviewed in Duerr et al., 2006). At present there is no
correlate of protection leaving vaccine development an em-
pirical effort. Thus, there is good reason to continue to ex-
pand potential vaccine strategies that may offer distinct
advantages.
Materials and methods
Construction of the single cycle vector SIVsmH4i-SC27.1
A 1655-bp fragment (Fragment A, nucleotides 155–1811)
that included the left LTR and part of gag gene from the
infectious molecular clone SIVsmH4i (GenBank No: X14307)
was subcloned into the Zero Blunt PCR-vector (Invitrogen, Cat.
K2700-20) after amplification by PCR. The amplicon truncated
155 bp at the left end of the upstream LTR to remove overlap
with the mutated regions of the nef gene present in the
downstream LTR. An EagI site was included in the left end, and
a polylinker BsrG1-BclI-ClaI-BglII-MluI was included in the
right end of the fragment to facilitate the subsequent cloning
steps. Four other amplicons representing the downstream
portions of the genome were generated guided by convenient
restriction enzyme sites to aid in the reassembly of the full-
length genome (fragment B, nucleotides 1739–5125, 3385 bp;
fragment C, nucleotides 5101–8044, 2914 bp; fragment D,
nucleotides 8034–8898, 808 bp; and fragment E, 8842–10241,
1395 bp). Each of the individual amplicons was subcloned as a
blunt-end PCR product.
The subcloned fragments were used as templates for mu-
tagenesis using the Quick-Change mutagenesis protocol where
the entire plasmid is resynthesized by PCR using complemen-
tary mutagenic primers. After adding mutations to each of the
fragments, the genome was reassembled by adding the frag-
ments back sequentially, using the polylinker and unique re-
striction sites within the genome to build the single cycle vector
SC27.1. The reassembled genome was fully sequenced to val-
idate its structure.
Vesicular stomatitis virus glycoprotein (VSV G)
Three serotypes of vesicular stomatitis virus glycoprotein
(VSV G) were included in this study. A plasmid containing the
Indiana strain glycoprotein [G(I)] in the expression vector pCI
was kindly provided by Dr. John Olsen. Clones of two other
serotypes of the VSV G gene, from the New Jersey [G(NJ)] and
the Chandipura [G(Ch)] strains, were a gift from Dr. John Rose
and Dr. Amiya Banerjee, respectively. To put the VSV G(NJ)
and the VSV G(Ch) genes into the same expression vector as
pCI-G(I) clone, we created an AvrII site after the stop codon of
the VSV G(I) gene in the pCI vector. The VSV G(NJ) gene and
the VSV G(Ch) gene were then amplified by PCR. XhoI and
NheI sites were included in the forward and reverse primers,
respectively. The PCR product was digested with XhoI and
NheI and cloned into the modified pCI/VSV G(I) vector,
which had been digested with XhoI and AvrII to remove the
VSV G(I) insert. The new plasmids were designated pCI-G(NJ)
and pCI-G(Ch).
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The 293T cell line was maintained in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% fetal calf
serum. Cells were seeded at 5×106 cells per 150-mm plate the
day before transfection. VSV G-pseudotyped virus was
prepared by mixing the cloned SC27.1 plasmid and one of the
VSV G expression vectors with the FuGENE6 transfection
reagent (Roche, Cat. 11814443001) following the manufac-
turer's instructions. The transfection mix was removed after 6 h,
the cells washed, and 15 ml of serum-free medium added
(Invitrogen, Cat. 12338-018). The culture supernatant contain-
ing virus particles was harvested 48 h later and either used for
infection directly or concentrated by pelleting at 14,000 rpm for
3 h by ultracentrifugation with or without a 20% sucrose
cushion (Beckman SW28i); virion pellets were resuspended in
PBS. The virus stocks were aliquoted and stored at −80 °C.
CA p27 quantification and infectivity assay
Quantification of the viral p27 CA protein in purified virus or
virus-containing supernatant was done using an SIV p27 Antigen
ELISA kit (Zeptometrix Corp.) according to the manufacturer's
instructions. Denaturing gel electrophoresis followed by silver
staining of the proteins was also used to quantify p27 based on a
comparison to a dilution series of a known amount of a virus stock
(SIVmac239/SUPT1-CCR5, obtained from AIDS Vaccine Pro-
gram, National Cancer Institute at Frederick). Infectivity assays
were performed in TZM-BL indicator cells, which contain the
luciferase gene and LacZ gene under control of HIV LTR (Wei
et al., 2002, and obtained from NIH AIDS Research and
Reference Reagent Program). Virus stocks were serially diluted
inDMEMmedium and used to infect TZM-BL cells (2×104 cells
per well of a 96-well plate in a volume of 200 μl, or 4×104 cells
per well of a 24-well plate in a volume of 400 μl), in presence of
20 μg/ml DEAE dextran. After a 48-h incubation, the culture
medium was removed from each well and the cells were rinsed
with PBS. An aliquot of 80 μl of Reporter lysis buffer (Promega
Corp.) was added to each well of the 96-well plate for the
luciferase assay. After one freeze–thaw cycle, 75 μl of cell lysate
was used for measurement of luciferase activity using a
luminometer. For X-gal staining, 48 h after infection, cells were
fixed in 200 μl of fixing solution (1% formaldehyde, 0.2%
glutaraldehyde in PBS) at room temperature for 5 min, the fixing
solution was removed and the cells rinsed twice with PBS. Cells
were then stainedwith 200μl staining buffer (stock is 9.5ml PBS,
200 μl 0.2 M potassium ferrocyanide, 200 μl of 0.2 M potassium
ferricyanide, 10 μl of 2 M MgCl2, 100 μl of 40 mg/ml X-gal
stock) at 37 °C for 2 h, washed, and infectious units counted as
blue-cell forming units (BFU) using light microscopy.
Protein analysis of virions and cell lysates
Concentrated and purified virions were prepared as de-
scribed above. Cell lysates were prepared by harvesting the cell
monolayer from a 100-mm plate in 2 ml of NP-40 lysis buffer
(0.05 M Tris, pH 7.5; 0.1 M NaCl, 0.002 M EDTA; 0.2% NP-40and 1 protease inhibitor tablet per 25 ml, Roche, Cat# 1873580)
2 days after transfection. Samples were stored at −80 °C until
use. For western blot analysis, samples were mixed with gel
loading dye, heated at 70 °C for 10 min, then the proteins
separated by electrophoresis in a 4–12% SDS–polyacrylamide
gel (NuPAGE Novex Bis–Tris Gels, Invitrogen). The proteins
were transferred out of the gel onto a Hybond-P PVDF
membrane (Amersham Biosciences, NJ, USA) according to
standard procedures; the blots were then blocked in 3%
membrane blocking agent (Amersham Biosciences, NJ, USA)
in PBS with 0.1% Tween, then probed with serum pooled from
SIVsm-infected macaques, an SIV Env monoclonal antibody
(36D5, a gift from Dr. Jim Hoxie), or an SIVmac251 Gag
Monoclonal antibody (KK64, obtained from the NIH AIDS
Research and Reference Reagent Program) at a 1:000 dilution.
Blots were then incubated with horseradish peroxidase (HRP)-
conjugated, anti-human (1:2000) or anti-mouse immunoglobulin
G (1:2000) secondary antibodies (Promega, San Luis ObispoCA)
and developed with chemiluminescent substrate (Amersham
Biosciences, NJ, USA.). Bands were visualized by using Kodak
BioMax MR Film.
Expression of labeled viral proteins in cultures infected with
either SC27.1 or wild-type virus was analyzed radioimmunopre-
cipitation. Briefly, infected TZM-BL cells were washed then
starved in serum-free, cysteine and methionine-free DMEM
medium for 2 h. The cells were labeled overnight by supplement-
ing the medium with 100 μCi/ml S35-Trans Label (ICN Radio-
chemicals, Costa Mesa, CA). Serum pooled from SIVsm-infected
macaques or SIV Env Monoclonal (36D5) or SIVmac251 Gag
Monoclonal (KK64) were used to isolate viral proteins.
Antibodies were added to cells and virus lysates and incubated
overnight at 4 °Cwith rocking. Protein A and/or Protein G agarose
beads were added and the incubation continued for a further 2 h.
The beads were washed twice with NP-40 lysis buffer, then boiled
in gel loading buffer; the eluted proteins were separated by gel
electrophoresis in a 4–12% SDS–polyacrylamide gel. After
electrophoresis, the gel was placed on a filter paper and dried in a
gel dryer. Dried gels were exposed to X-ray film.
Analysis of SC27.1 Vif function
The activity of the mutant Vif protein in SC27.1 was measured
in a single-cycle infectivity assay in presence of APOBEC3G.
293Tcells were transfected with SC27.1/pCI VSVG orwild-type
virus, together with pcDNA-APO3G (obtained from the NIH
AIDS Research and Reference Reagent Program) at a plasmid
molar ratio of 1:10; 1:20; 1:50 and 1:100 (the amount of SC27.1
and wild-type SIVsmH4i was fixed at 2.5 μg per well in a 6-well
plate; the SC27.1/pCI VSV G molar ratio was 1:10). Supernatant
virus was harvested at 48 h and used to infect TZM-BL cells as
described above. The infectivity titer and p27 titer were
determined as described above.
Analysis of Env surface expression
Fragments of SC27.1 or SIVsmH4i env sequence were
amplified using PCR and cloned into theVEE replicon expression
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EcoRV and AscI sites to give the plasmid pERK-SC27.1gp155,
pERK-SIVsmH4igp155 (truncated at same position as SC27.1
env), and full-length pERK-SIVsmH4igp160. Plasmid DNA
was prepared with the Qiagen HiSpeed Plasmid Maxi Kit.
Purified plasmid DNA was linearized with NotI, and RNA
transcribed in vitro using the Ambion mMESSAGE mMA-
CHINE T7 kit. Vero cells were electroporated with RNA using a
BioRAD GenePulser. Cells were pulsed four times at 450 volts,
50 μF capacitance, then harvested 48 h later. Expression of Env
was determined by staining the intact cells with the anti-SIV Env
antibody 36D5, using anti-mouse antibody conjugated with APC
as the second antibody. Env surface and intracellular expression
were analyzed with a Beckman FACSCalibur.
Neutralization assays of pseudotyped SC27.1
A neutralizing rabbit antiserum to VSV G(I) (a gift from
Dr. John Rose, Yale University) was used to detect antibody
neutralizing activity to the three VSV G-pseudotyped single
cycle virus preparations and wild-type SIV. Neutralization as-
says were performed as follows: the rabbit serum was diluted
with DMEM complete medium in a volume of 50 μl in serial
two-fold dilutions in 96-well plates. An aliquot of 50 μl of each
virus in DMEM complete medium was added to the diluted
antiserum in each well. The 96-well plate containing antiserum
and virus was incubated at 37 °C for 1 h. Approximately 2×104
TZM-BL cells in 100 μl of DMEM–10% FBS were then added
to each well. The plates were incubated at 37° for 2 days. The
infectivity titer was determined by luciferase assay as described
above. A similar protocol was used to test human and macaque
sera for innate neutralizing activity. Serum samples were ob-
tained from human donors and macaques and stored frozen. The
sera were thawed and half of each serum sample was heated at
56 °C for 1 h to inactivate the complement. Viral particles were
incubated 1 h at 37 °C in 100 μl with 50% of normal or heat-
inactivated serum (or medium containing 10% heat-inactivated
FBS as the no-serum control) and were subsequently tittered on
TZM-BL cells to assess virus survival. Data were calculated as
percent virus survival in the various sera relative to the titer of
virus in the no serum control (but with 10% FBS). All serum
samples were analyzed for hemolytic complement activity using
a kit from Diamedix (EZ complement CH50 Test; Miami, FL).
Detection of replication competent viruses
Pseudotyped virus generated by transfection of 293T cells
with SC27.1 and pCI-G was used to infect 3×106 CEM×174
cells at an MOI of 1. Wild-type virus and SC27.1 virus in the
absence of VSV G pseudotype were also used to infect cells.
Doses of MOI 1, 0.1, and 0.01 were used for the wild-type virus
to infect cells. The infection was done in 48-well plates with a
total volume of 250 μl in each well. After incubation for 4 h,
cells were washed in PBS and cultured in 25 mm flasks in 10 ml
RPMI medium containing 10% FCS. Every other day, the
supernatant was collected and half of the cells were removed,
the remaining cells were maintained with 10 ml fresh medium.When syncytium formation was observed in the low dose wild-
type virus (MOI of 0.01), the supernatant medium from each of
the cultures was used to infect fresh CEM×174 cells (passage
2). Cells were maintained as described above and the passage
repeated once more (passage 3). Each passage cultures was
maintained for up to 2 weeks. Supernatants collected at various
time points were analyzed for p27 level by ELISA.
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